Sept. 3rd Deadline ALERT: Investors Who Lost More Than $100,000 With Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) Shares Should Contact the Shareholders Foundation

SAN DIEGO, CA, August 28, 2024 (Newswire.com) - The Shareholders Foundation, Inc. announced that September 03, 2024, a deadline is coming up in the lawsuit that was filed for certain investors who purchased shares of Bolt Biotherapeutics, Inc. (NASDAQ:BOLT). Investors in NASDAQ: BOLT should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The Shareholders Foundation, Inc. announced that September 03, 2024, a deadline is coming up in the lawsuit that was filed for certain investors who purchased shares of Bolt Biotherapeutics, Inc. (NASDAQ:BOLT).

Investors, who purchased shares in excess of $100,000 of Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) between February 5, 2021 and May 14, 2024, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

On May 14, 2024, Bolt Biotherapeutics, Inc announced that it would cease further development of its lead asset BDC-1001 and focus resources on BDC-3042 and BDC-4182 upon determining that BDC-1001 failed to meet its pre-defined success criteria, that the Company's Chief Executive Officer ("CEO") Randall C. Schatzman and Chief Medical Officer ("CMO") Edith Perez would be moved into advisory roles, and that Bolt would be reducing its workforce by approximately 50%.

On July 02, 2024, an investor in NASDAQ: BOLT shares filed a lawsuit against Bolt Biotherapeutics, Inc.. The plaintiff alleges that the defendants made false and/or misleading statements and/or failed to disclose that BDC-1001 was less effective than the Company had represented to investors and was in fact unlikely to meet its pre-defined success criteria, that accordingly, Defendants overstated the clinical and/or commercial prospects of Bolt's product pipeline, on which the Company primarily relies to sustain its business model, that all of the foregoing subjected the Company to a heightened risk of disruptive leadership transitions and substantial workforce reduction.

Those who purchased Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) shares should contact the Shareholders Foundation, Inc.

CONTACT:

Shareholders Foundation, Inc.
Michael Daniels
+1 (858) 779-1554
mail@shareholdersfoundation.com
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108

The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. Any referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is only provided as a public service. It is not intended as legal advice and should not be relied upon.

Contact Information

Michael Daniels
Manager
mail@shareholdersfoundation.com
858-779-1554

SOURCE: Shareholders Foundation, Inc.

Source: Shareholders Foundation, Inc.

Related Media